The Claim

Among cognitively unimpaired individuals with amyloid-beta pathology, the combination of elevated plasma p-tau217 and tau-PET positivity is associated with a 9.98-fold higher hazard of progressing to advanced biological stages of Alzheimer’s disease and a 3.03-fold higher hazard of developing clinical cognitive impairment over five years compared to individuals negative for both biomarkers.

Source: Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer’s disease

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
65score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

In people without cognitive symptoms but with amyloid-beta buildup in the brain, those with both high levels of p-tau217 in the blood and positive tau-PET scans have nearly 10 times greater risk of advancing to later Alzheimer’s disease stages and three times greater risk of developing cognitive impairment within five years compared to those without either biomarker abnormality.

See the scientific wording

Among cognitively unimpaired individuals with amyloid-beta pathology, the combination of elevated plasma p-tau217 and tau-PET positivity identifies a subgroup with 9.98-fold higher hazard of progressing to advanced biological stages of Alzheimer’s disease and 3.03-fold higher hazard of developing clinical cognitive impairment over five years compared to those negative for both biomarkers.

Why this might work

Amyloid buildup in the brain causes tau proteins to become abnormally phosphorylated, which makes them clump together and spread from deep brain regions to the outer cortex. As these clumps accumulate, they kill nerve cells and shrink brain tissue, leading to memory and thinking problems.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer’s disease

    In older adults with early Alzheimer’s brain changes but no symptoms, those with both a high blood marker for tau and visible tau tangles on a brain scan are much more likely to get worse over five years than those without these signs.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.